Stay updated on Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.

Latest updates to the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPublications section now notes that entries are automatically filled from PubMed, replacing the previous wording; revision tag updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the government funding operating status banner that informed users about potential delays and provided links to cc.nih.gov and opm.gov.SummaryDifference0.3%

- Check42 days agoChange DetectedThe update shows a newer last update date and minor formatting changes; core study details, eligibility criteria, and enrollment remain unchanged.SummaryDifference0.4%

- Check64 days agoChange DetectedThe page updated how it displays the last update timestamp: replaced 'Last Update Posted' with 'Last Update Posted (Estimated)'.SummaryDifference0.0%

- Check71 days agoChange DetectedCore content and versioning updated: added a government-operating-status notice and new version/date metadata; removed older dates and revision v3.1.0.SummaryDifference3%

- Check78 days agoChange DetectedUpgrade version from v3.0.2 to v3.1.0 with an added update marker; no substantive content or critical data changes detected.SummaryDifference0.3%

Stay in the know with updates to Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.